Methods of therapy using pharmaceutical composition for thrombin peptide derivatives
Disclosed are pharmaceutical compositions comprising a thrombin peptide derivatives and a chelating agent and/or a pharmaceutically acceptable thiol-containing compound. The pharmaceutical compositions optionally further comprise an antioxidant. Also, disclosed are methods for activating the non-proteolytically activated thrombin receptor in a subject in need of such treatment. The methods comprise the step of administering an effective amount of a thrombin peptide derivative in the pharmaceutical composition described above.
1. A method for activating the non-proteolytically activated thrombin receptor in a subject in need of such treatment, said method comprising administering to the subject an effective amount of a pharmaceutical composition comprising:
a) a 23 amino acid polypeptide, wherein the amino acid of the polypeptide is Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO:3); and
b) a chelating agent for binding to a metal ion; and/or a pharmaceutically acceptable thiol-containing compound.
2. The method of claim 1 wherein the pharmaceutical composition additionally comprises an antioxidant.
3. The method of claim 2 , wherein the antioxidant is selected from the group consisting of tocopherol, methionine, glutathione, tocotrienol, dimethyl glycine, betaine, butylated hydroxyanisole, butylated hydroxytoluene, turmerin, vitamin E, ascorbic acid, ascorbyl palmitate and thioglycolic acid.
4. The method of claim 2 , wherein the pharmaceutical composition comprises a chelating agent for binding to a metal ion; and an antioxidant.
5. The method of claim 4 , wherein the antioxidant is methionine.
6. The method of claim 1 , wherein the pharmaceutical composition comprises a copper-chelating agent.
7. The method of claim 6 , wherein the copper-chelating agent is selected from the group consisting of diethylenetriaminepentacetic acid (DTPA) and bathophenanthroline disulfonic acid (BPADA).
8. The method of claim 6 , wherein the copper-chelating agent is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), penicillamine, trientine, N,N′-diethyldithiocarbamate (DDC), 2,3,2′-tetraamine (2,3,2′-tet), neocuproine, N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), 1,10-phenanthroline (PHE), tetraethylenepentamine, triethylenetetraamine and tris(2-carboxyethyl) phosphine (TCEP).
9. The method of claim 6 wherein the pharmaceutical composition comprises a pharmaceutically acceptable thiol-containing compound.
10. The method of claim 1 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable thiol-containing compound selected from the group consisting of thioglycerol, mercaptoethanol, thioglycol, thiodiglycol, thioglucose, dithiothreitol (DTT), and dithio-bis-maleimidoethane (DTME).
11. The method of claim 1 , wherein the subject is in need of treatment to promote cartilage growth or repair.
12. The method of claim 1 , wherein the subject is in need of bone growth.
13. The method of claim 1 , wherein the subject is in need of treatment to promote wound healing.
14. The method of claim 13 , wherein the wound is a chronic wound.
15. The method of claim 1 wherein the subject is in need of treatment to promote cardiac repair or inhibit restenosis.
16. A method for activating the non-proteolytically activated thrombin receptor in a subject in need of such treatment, said method comprising the step of administering to the subject an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising:
a) a thrombin peptide derivative, wherein the throbin peptide dervative is the polypeptide: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-NH 2 (SEQ ID NO:4); and
b) a chelating agent for binding to a metal ion; and/or a pharmaceutically acceptable thiol-containing compound.
17. The method of claim 16 , wherein the pharmaceutical composition further comprises an antioxidant.
18. The method of claim 16 , wherein the pharmaceutical composition comprises a copper chelating agent.
19. The method of claim 16 , wherein the subject is in need of treatment to promote cartilage growth or repair.
20. The method of claim 16 , wherein the subject is in need of bone growth.
21. The method of claim 16 , wherein the subject is in need of treatment to promote wound healing.
22. The method of claim 21 , wherein the wound is a chronic wound.
23. The method of claim 16 , wherein the subject is in need of treatment to promote cardiac repair or inhibit restenosis.